Fully invested in Expertise
Our Team
Launch Therapeutics is backed by leading investors, Carlyle and its life sciences franchise, Abingworth.
Launch Tx was formed in 2022 with the vision of assembling an exceptional team that could redefine late-stage development. The goal? Expediting the pathway for therapies to be approved, and ultimately, delivered to the patients who need them. Meet the team of passionate professionals who are deeply committed to both the science – and the art – of delivering on that promise.
Executive Leadership
Board of Directors
Advisors
Elisha Talley
President
Jonathan DeBenedetto
Chief Financial Officer
Shao Chang, MD, PHD
SVP, Chief Medical Officer
Laura Batchelor
SVP, Corporate Development & Alliance Management
James Cornwall
SVP, Business Development
Matthew Cramblett
Head of Delivery Operations
Haley Hopkins
Head of Human Resources
Bali Muralidhar
Managing Partner, Chief Investment Officer & COO, Abingworth
Kurt von Emster, CFA
Managing Partner and Head of Abingworth Life Sciences, Abingworth
Joe Bress
Managing Director, Carlyle
William Sharbaugh
Former President & COO, PPD
Steve Wise
Managing Director & Global Head of Healthcare, Carlyle
Carlos Paya, MD, PHD
Former CEO, Immune Design
Michael Doherty
Former Chief of Regulatory Affairs, EQRX
Ian Read
Former Chairman & CEO, Pfizer
Laura Hamill
Former EVP, Worldwide Commercial Operations, Gilead
Together, We Deliver Excellence
Founded in 2022, Launch Tx has already made its mark — powering remarkable success across partnered programs.
6
Phase III Studies
955+
Sites
85+
Countries
4,200+
Patients